The Latest Breaking News on Pharma

The U.S. Food and Drug Administration (FDA) has warned against using an eye drop made in India that has been linked to the outbreak of a drug-resistant bacteria leading to adverse events in at least 55 patients in the United States including infections, blindness and one death.

Regeneron Pharma beat quarterly forecasts Friday, but its partner Sanofi posted a mixed report. Regeneron stock rose as SNY stock toppled.

Health sector welcomes the broad vision of taskforce report, but worries it’s short on details, a timeline and money

From July, authorised psychiatrists will be able to prescribe the drugs for post-traumatic stress disorder and severe depression

An interim decision by the medicines regulator would prevent Australians from buying packs of up to 100 paracetamol tablets without speaking to a pharmacist.

Gilead Sciences followed up a strong quarterly report with a third FDA approval for cancer drug Trodelvy, and GILD stock popped.

Biohaven is taking the same tact that led to a nearly $12 billion Pfizer buyout with the rest of its pipeline — and BHVN stock has soared.

U.S. health officials are advising people to stop using over-the-counter eye drops that have been linked to an outbreak of drug-resistant infections

The pharmaceutical industry is well-positioned for significant growth in the near future, given the growing demand for medicines and increasing R&D activities. Given the industry's inelastic demand, fundamentally strong pharma stocks AstraZeneca (AZN), Bristol-Myers Squibb (BMY), and GSK plc (GSK) might be solid long-term investments. Continue reading….

Merck's profit guidance for 2023 widely missed Wall Street's projections on Thursday, leading Merck stock to crumble despite a quarterly beat.

Eli Lilly experienced a "bump in the road" for its newest diabetes treatment, Mounjaro, an analyst said Thursday as LLY stock toppled.